TW200942819A - Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB) - Google Patents
Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)Info
- Publication number
- TW200942819A TW200942819A TW098108600A TW98108600A TW200942819A TW 200942819 A TW200942819 A TW 200942819A TW 098108600 A TW098108600 A TW 098108600A TW 98108600 A TW98108600 A TW 98108600A TW 200942819 A TW200942819 A TW 200942819A
- Authority
- TW
- Taiwan
- Prior art keywords
- alzheimer
- disease
- methods
- specific
- cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/078,857 US20080221042A1 (en) | 2005-10-11 | 2008-04-07 | Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB) |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200942819A true TW200942819A (en) | 2009-10-16 |
Family
ID=41037627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW098108600A TW200942819A (en) | 2008-04-07 | 2009-03-17 | Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB) |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2263090A1 (zh) |
JP (1) | JP2011516883A (zh) |
KR (1) | KR20100132997A (zh) |
AU (1) | AU2009234405A1 (zh) |
BR (1) | BRPI0911073A2 (zh) |
CA (1) | CA2720621A1 (zh) |
IL (1) | IL208296A0 (zh) |
TW (1) | TW200942819A (zh) |
WO (1) | WO2009126232A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015103495A1 (en) * | 2014-01-03 | 2015-07-09 | Blanchette Rockefeller Neurosciences Institute | Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease |
EP3600027A4 (en) | 2017-03-31 | 2020-12-23 | Neurodiagnostics LLC | LYMPHOCYTE-BASED MORPHOMETRIC TEST FOR ALZHEIMER'S MORBUS |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007043998A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
-
2009
- 2009-03-17 TW TW098108600A patent/TW200942819A/zh unknown
- 2009-04-03 EP EP09731007A patent/EP2263090A1/en not_active Withdrawn
- 2009-04-03 AU AU2009234405A patent/AU2009234405A1/en not_active Abandoned
- 2009-04-03 JP JP2011503976A patent/JP2011516883A/ja active Pending
- 2009-04-03 KR KR1020107024733A patent/KR20100132997A/ko not_active Application Discontinuation
- 2009-04-03 BR BRPI0911073A patent/BRPI0911073A2/pt not_active IP Right Cessation
- 2009-04-03 WO PCT/US2009/002120 patent/WO2009126232A1/en active Application Filing
- 2009-04-03 CA CA2720621A patent/CA2720621A1/en not_active Abandoned
-
2010
- 2010-09-21 IL IL208296A patent/IL208296A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0911073A2 (pt) | 2019-09-24 |
WO2009126232A1 (en) | 2009-10-15 |
AU2009234405A1 (en) | 2009-10-15 |
CA2720621A1 (en) | 2009-10-15 |
EP2263090A1 (en) | 2010-12-22 |
KR20100132997A (ko) | 2010-12-20 |
JP2011516883A (ja) | 2011-05-26 |
IL208296A0 (en) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200801515A (en) | Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio- alzheimer's disease-specific molecular biomarkers (ADSMB) | |
WO2007047029A3 (en) | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) | |
EP3540442A1 (en) | Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof | |
Jorge et al. | Statistical Model to Analyze Quantitative Proteomics Data Obtained by 18O/16O Labeling and Linear Ion Trap Mass Spectrometry: Application to the Study of Vascular Endothelial Growth Factor-induced Angiogenesis in Endothelial Cells* S | |
JP5878875B2 (ja) | アルツハイマー病の診断法 | |
US20090011452A1 (en) | Method of Prognosis of Mental Diseases, E.G. Autism and Cerebral Palsy | |
EP3015865A1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
RU2011150279A (ru) | Фосфодиэстераза 4d7 как маркер рака предстательной железы | |
ATE536553T1 (de) | Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse | |
EP3088899B1 (en) | Biomarkers for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers | |
JP2015105951A (ja) | 血液由来の癌診断用ペプチドマーカー及びそれを用いた癌診断方法 | |
KR20120125157A (ko) | 렉틴을 이용한 암 진단 방법 | |
ATE370414T1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
JP2024096748A (ja) | アルファ-シヌクレイン病のアッセイ、方法、及び治療 | |
US20020006627A1 (en) | Method for diagnosis of Alzheimer's disease | |
Yang et al. | An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression | |
US20140018299A1 (en) | Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury | |
RU2011150291A (ru) | Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы | |
TW200942819A (en) | Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB) | |
CN109073661B (zh) | 用于神经学疾病的诊断的测定法 | |
KR100925147B1 (ko) | 폐암 진단용 마커 | |
CN103983787A (zh) | 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 | |
WO2012175674A1 (en) | Diagnosis and/or prognosis of a neurodegenerative disease | |
KR101219516B1 (ko) | 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법 | |
KR102254053B1 (ko) | 인지기능 정상군 또는 경도 인지장애에서 아밀로이드 베타의 뇌 침착 검출용 혈액 바이오 마커 |